Management of Relapsed/Refractory Multiple Myeloma

The treatment of relapsed multiple myeloma is based in part on the degree previous exposure and resistance to commonly used drug classes. For patients with a first relapse, an anti-CD38 antibody–based combination preferred unless have already received these agents, which case carfilzomib-based option can be excellent choice. more refractory disease, bispecific antibody emerging choice, but CAR T-cell therapy should also considered for some patients; other options include salvage autologous transplantation, recycling therapies, selinexor-based therapies. Emerging new classes drugs development are poised broaden possibilities disease.